Sort
48,018 grants matching “immunotherapy”
IMMUNOTHERAPY OF ALZHEIMER'S DISEASE
$378,083Boston Biotechnology Corporation · R44 · FY2000 · AG
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
$378,030Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2021 · CA
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
$378,023Hassane M Zarour · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · CA
Project 3: Localized microneedle-directed combination immunotherapy for cSCC
$378,023Louis D Falo · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · CA
LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer
$378,023Da Yang · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Project 1: Evaluating the synergy of LAG3 and PD-1 in melanoma patients
$378,022Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · CA
The B7x pathways in the tumor microenvironment
$378,000Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2024 · CA
Tumor-expressed immune checkpoint B7x-mediated resistance to anti-CTLA-4 therapy.
$378,000Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2022 · CA
Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response
$377,999Mercedes R. Rincon · University Of Colorado Denver · R01 · FY2025 · CA
Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response
$377,999Mercedes R. Rincon · University Of Colorado Denver · R01 · FY2022 · CA
Scientific Core B
$377,994Holden T. Maecker · Stanford University · U19 · FY2013 · AI
eDyNAmiC - NYU
$377,904Jef D Boeke · New York University School Of Medicine · OT2 · FY2025 · CA
Direct Targeting of MYC in Cancer with Hyperstable Synthetic Transcriptional Repressors
$377,870Raymond E Moellering · University Of Chicago · R01 · FY2025 · CA
Direct Targeting of MYC in Cancer with Hyperstable Synthetic Transcriptional Repressors
$377,870Raymond E Moellering · University Of Chicago · R01 · FY2024 · CA
Regulation of gamma delta T cell immunoediting by novel phosphoantigens
$377,822Andrew J Wiemer · University Of Connecticut Storrs · R01 · FY2017 · CA
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
$377,814Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2010 · NS
Innate and Adaptive Anti-Myeloma Immunity
$377,781Nikhil C. Munshi · Dana-Farber Cancer Inst · P01 · FY2011 · CA
Mechanisms of Resistance to Gemtuzumab Ozogamicin
$377,778Fred Hutchinson Cancer Research Center · R01 · FY2003 · CA
An integrative structural biology approach to the study of T cell signaling
$377,776Nikolaos Sgourakis · University Of California Santa Cruz · R35 · FY2017 · GM
An integrative structural biology approach to the study of T cell signaling
$377,776Nikolaos Sgourakis · University Of California Santa Cruz · R35 · FY2018 · GM
Liquid biopsy of the lung to profile lung cancer
$377,741Viswam Siva Nair · Fred Hutchinson Cancer Center · U01 · FY2024 · CA
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
$377,735Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Quality and location of presented Ag as determinants of tumor-specific immunity
$377,734Victor H. Engelhard · University Of Virginia · R01 · FY2010 · CA
Autoimmune vitiligo and tolerance in the immune response to a melanoma antigen
$377,720Victor H. Engelhard · University Of Virginia · R01 · FY2007 · AI
Project 1: Murine Modeling of Tumor-Mediated Immunosuppression
$377,697Edgar G. Engleman · Stanford University · U54 · FY2020 · CA